Obermatt
See Similar Stocks →

Hypera

SAO:HYPE3 · BRHYPEACNOR0
PharmaceuticalsMedium

360

90
EV / EBIT80
Price / Owner Earnings51
Owner Earnings Yield78
Dividend Yield85
Price/Sales85
EV / Gross Profit64
Price/Book94
Return on Capital61
Cash Return on Capital45
Return on Equity55
EBIT Margin86
Gross Profitability30
Cash Conversion79
Accruals69
Owner Earnings Margin58
Sales growth88
Profit Growth79
Long-Term EPS Growth78
Owner Earnings Growth89
Reinvestment97
Price momentum29
Debt load18
Refinancing71
Debt Payback15
Liquidity18
Analyst ratings49
Opinion Changes68
Price Target Upside44
Market mood17
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Hypera generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryBrazil
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeBOVESPA
Employees3,773
ISINBRHYPEACNOR0
Last UpdateApr 2, 2026
Indices
BOVESPA (Brazil)Renewable Energy Users
Themes
Pain ManagementFast-Moving Consumer GoodsNutraceuticalBeautyPersonal HealthPharmaceutical

Description

Analysis

Bargain bin

Hypera S.A. is priced cheaply, and that invites the natural question of why, since the underlying business scores below average.

On valuation, the picture is attractive. The owner-earnings multiple stands at 10.9×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around -2% a year, against analyst forecasts of 21%. The price, in other words, assumes less than the experts do.

Growth is solid; the safety picture is stretched. The company scores 14/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
73
2023202420252026

All-time high

89

Aug 2023

All-time low

22

Nov 2024

Average rank

56

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
85
79
71
78
Price/Earnings
95
93
93
97
Price/Book
94
82
82
88
Dividend Yield
85
92
98
90
Value (overall)
98
89
95
87

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Hypera with its peers
Mega Lifesciences
SET:MEGA
78
CountryThailand
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Glenmark Pharmaceuticals
NSI:GLENMARK
58
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Dr. Reddy's
NSI:DRREDDY
29
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Bangkok Lab and Cosmetic
SET:BLC
55
CountryThailand
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Torrent Pharmaceuticals
NSI:TORNTPHARM
18
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Aurobindo Pharma
NSI:AUROPHARMA
60
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →